Gilead Sciences Inc. is asking the Food and Drug Administration for the second time in a year to approve its experimental twice-a-year HIV-fighting drug lenacapavir.
The FDA in February rejected the drug after determining the borosilicate glass vials holding the drug were not compatible with the drug. Foster City-based Gilead (NASDAQ: GILD) said Monday said its new application for approval includes data for lenacapavir in vials made from aluminosilicate glass.
